'One of the lucky few': Bicara's CEO on operating in today's market, while hoping for a different one
Amid an FDA overhaul and market volatility, one biotech executive says her public company still operates with the mentality of a private company, while urging the industry to work together with federal health agencies so drug developers can continue to transform cancer care.
Amid an FDA overhaul and market volatility, one biotech executive says her public company still operates with the mentality of a private company, while urging the industry to work together with federal health agencies so drug developers can continue to transform cancer care.
